Algen Biotechnologies GTM brain

Algen develops medicines and works with pharmaceutical partners on target discovery using CRISPR gene modulation and AI.

category

CRISPR and AI drug discovery

market profile

  • text: Algen combines an internal therapeutic pipeline with pharmaceutical collaborations; its AstraZeneca immunology deal was reported as worth up to $555 million including milestones.
  • text: Drug discovery partners use functional genomics and AI to identify disease-driving targets in complex biology.

personas

  • title: Pharmaceutical discovery or immunology research leader
    pains:
    • Complex inflammatory biology makes causal targets difficult to prioritize
    • Weak target validation can waste years of preclinical work
  • title: Pharma business development and external innovation leader
    pains:
    • Finding differentiated target discovery platforms with credible biological evidence
    • Negotiating rights, milestones and downstream development responsibilities

icp

  • text: Pharmaceutical companies with discovery budgets and immunology or oncology programs are plausible partners; AstraZeneca is a disclosed example.
  • text: Biotech R&D organizations seeking target discovery collaborations in diseases with substantial unmet need are a prospective fit; minimum firm size is not public.

message pillars

  • text: Use CRISPR and AI to discover therapeutics.
  • text: Identify causal biology by modeling disease progression.
  • text: Use precise gene modulation to unpack complex biology.

objections

  • objection: Do target predictions translate into effective medicines?
    response: Review experimental validation, relevant disease models, development stage and human evidence; platform claims do not establish clinical efficacy.
  • objection: How do partnership rights and economics work?
    response: Negotiate program-specific rights and milestones; the disclosed AstraZeneca agreement is not a public rate card.

competitors

  • name: Recursion
    website: https://www.recursion.com
    why: AI-enabled drug discovery and development company competing for discovery partnerships and programs.
  • name: BenevolentAI
    why: AI-driven drug discovery company pursuing pharmaceutical discovery partnerships.
  • name: Insitro
    why: Uses machine learning and experimental data for therapeutic discovery and collaborations.

influencers

  • name: Chun-Hao Huang
    url: https://www.linkedin.com/posts/chun-hao-huang_algen-biotechnologies-announces-multi-target-activity-7380939619917361152-FCtj
    why: CEO and cofounder discussing the AstraZeneca partnership.

keywords

  • CRISPR target discovery
  • AI immunology drug discovery
  • single cell perturbation screening
  • RNA signaling drug targets
  • causal biology platform
  • oncology target discovery
  • pharma AI discovery partnerships

voice

  • scientific
  • ambitious
  • collaborative

signals

  • text: A pharma company announces a new immunology discovery initiative or external platform partnership, indicating a potential need for target discovery.
  • text: An R&D group seeks functional genomics or single-cell evidence for hard-to-validate disease pathways.

stack

  • CRISPR gene modulation
  • deep learning
  • single-cell genomics

pricing

model: unknown

motion

sales_led

channels

  • partnerships
  • scientific conferences
  • LinkedIn
  • press

confidence

medium

Founders

  • name: Chun-Hao Huang
    title: Founder/CEO
    role: CEO
    bio: Dr. Huang is Co-Founder and CEO of Algen, with the mission to revolutionize therapeutic discovery through CRISPR gene-modulation and frontier AI. A genetic engineer, drug developer and AI entrepreneur, he received postdoc fellow at UC Berkeley under Nobel Laureate Jennifer Doudna and pioneered disease-relevant models using CRISPR. Dr. Huang’s accolades include an Edison Award, TIME Best Inventions of 2026, and being named a Lindau Nobel Laureate Meeting Fellow and Innovators Under 35.
  • name: Christine Du
    title: Founder
    role: Founder
    bio: Co-Founder and CBO, Algen

Back to YC companies